Weekly Digest – August 2025 Weekly Digest – August 2025 04 August 2025: Alphamab Oncology announces IND application for innovative PD-L1/αvβ6 bispecific ADC JSKN022 was officially accepted by CDE Alphamab Oncology’s IND application for JSKN022, a first-in-class PD-L1/αvβ6 bispecific ADC, […]
Weekly Digest – August 2025 Weekly Digest – August 2025 01 August 2025: Mabwell announces IND application acceptance for CDH17-targeting ADC 7MW4911 from both NMPA and FDA Mabwell’s proprietary CDH17-targeting ADC 7MW4911 received IND acceptance from China’s NMPA and IND […]
Weekly Digest – August 2025 Weekly Digest – August 2025 07 August 2025: Henlius to initiate a Phase 1 multicenter study in US of its PD-L1 ADC HLX43 for the treatment of thymic carcinoma The U.S. FDA has approved Henlius to initiate a Phase 1 multicenter trial of […]
Weekly Digest – August 2025 Weekly Digest – August 2025 08 August 2025: Antengene’s ATG-022 clinical study achieves positive results, CR achieved in elderly gastric cancer patient In Antengene’s Phase 1/2 CLINCH study, its in-house CLDN18.2-targeting ADC ATG-022 achieved a […]
Weekly Digest – August 2025 Weekly Digest – August 2025 06 August 2025: Huadong Medicine’s innovative MUC-17 ADC HDM2012 completes dosing of first patient in Phase 1 clinical trial in China Huadong Medicine’s subsidiary, Sino-US Huadong, dosed the first patient […]
Weekly Digest – August 2025 Weekly Digest – August 2025 07 August 2025: Minghui raises $131M ‘pre-IPO’ round to bankroll JAK inhibitor launch, ADC trials Minghui Pharmaceutical raised $131M in a “pre-IPO” round to advance oncology programs, including multiple ADC […]
